U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07652762) titled 'IN10018 in Combination With Dalpiciclib for Progressive Meningiomas' on June 05.
Brief Summary: This open-label Phase Ib study will evaluate the safety, tolerability, and preliminary effectiveness of IN10018 in combination with dalpiciclib in adults with progressive meningiomas. Progressive meningiomas are tumors arising from the membranes surrounding the brain that have continued to grow or have returned after previous treatment.
Participants will receive both study drugs by mouth in 28-day treatment cycles. IN10018 will be taken once daily throughout each cycle, and dalpiciclib will be taken once daily for 21 days followed by 7 d...